Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, April 22, 2015

EASL 2015-RECOMMENDATIONS ON TREATMENT OF HEPATITIS C

Summary Of EASL Hepatitis C Treatment Guidelines
New EASL guidelines prioritise interferon-free hepatitis C treatment
Who should be treated?
Recommended regimes by genotype
Other considerations
Non-invasive liver disease assessment
What we need now: research gaps and improved access
Click here

Download: The European Association for the Study of the Liver (EASL) latest hepatitis C treatment guidelines

PDF:RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2015
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about 160 million, but most are unaware of their infection.

The implementation of extended criteria for screening for HCV is a subject of major debate among different stakeholders. Clinical care for patients with HCV-related liver disease has advanced considerably during the last two decades, thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention.

No comments:

Post a Comment